Companies to highlight data at Retina World Congress 2024
Several companies working in the retina space have shared that they plan to release data at this year’s meeting in Fort Lauderdale, Florida.
(Image credit: AdobeStock/aiisha)
Retina World Congress 2024 will be held in Fort Lauderdale, Florida on May 9-12. As presenters prepare for their talks, several companies have announced that they will release data at the event.
Note: The following list of presentations are in alphabetical order by company.
Alimera Sciences
A poster-on-demand by Michael Singer, MD, entitled “36-month Outcomes Following Treatment of Chronic Non-infectious Uveitis Affecting the Posterior Segment with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant: a CALM Registry Analysis” will highlight the company’s intravitreal implant used to reduce inflammation.1
Nanoscope Therapeutics
On May 9, 2024, Samarendra Mohanty, PhD, Chief Scientific Officer of Nanoscope Therapeutics, will present “Gene Therapy, Pharmacotherapy and Optogenetics for IRD.” This presentation will provide an update on MCO-010 gene therapy for IRDs and will be followed by a panel discussion moderated by Peter Kaiser, MD, Professor of Ophthalmology at Cole Eye Institute in Cleveland Clinic Lerner College of Medicine.2
On May 10, 2024, Christine Kay, MD, Director of Electrophysiology, Retinal Genetics, and Clinical Trials at Vitreoretinal Associates in Gainesville, Florida, and Affiliate Assistant Professor at the University of South Florida, will present. The session, entitled “Longitudinal BCVA and Safety Analysis of Mutation-Agnostic MCO-010 Optogenetic Therapy For Retinitis Pigmentosa: Patient Case From A Phase 2b Randomized, Sham-Controlled, Patient- And Assessor-Masked Clinical Trial (RESTORE)” will discuss the visual acuity observed during the RESTORE trial.2
Ocugen
Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen is set to speak at the Retina World Congress. He will be a part of the RWC Unplugged Panel Session: Gene Therapy, Pharmacotherapy and Optogenetics for IRD on May 9, 2024.3
The company also noted that the abstract, "Safety and Efficacy Results from a Phase 1/2 Clinical Trial of OCU400 Modifier Gene Therapy for Treatment of Retinitis Pigmentosa," has been accepted as an e-poster/video presentation. This abstract will be showcased in a video display during the conference.3
Opthea Limited
The company will share phase 2 clinical trial results and updates on the ongoing phase 3 clinical trial program for its lead product, OPT-302 (sozinibercept). On May 10, Jordana G. Fein, MD, MS, Retina Group of Washington, Fairfax, Virginia will give a presentation titled “Latest Trial Updates Regarding OPT-302.” On May 11, 2024, David Eichenbaum, MD, FASRS, Partner and Director of Research at Retina Vitreous Associates of Florida will present, “Rationale for the Design of the Phase 3 Superiority Clinical Trials of Sozinibercept Combination Therapy Targeting Inhibition of VEGF-C/-D and VEGF-A for Neovascular Age-Related Macular Degeneration.”
The company’s CEO, Frederic Guerard, PharmD, will also participate in the RWC Unplugged panel discussion on May 9, 2024.4
Outlook Therapeutics
Russell Trenary, President and Chief Executive Officer for the company will also participate int RWC Unplugged. In this panel session, he will discuss Outlook Therapeutics’ ONS-5010/LYTENAVA™, an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD via intravitreal injection.5
